

18 January 2024

Deltex Medical Group plc
(“Deltex Medical”, the “Company” or the “Group”)

Issue of equity to satisfy equity-settled non-executive directors’ fees

The Board of Deltex Medical (AIM: DEMG), announces the issue of 49,372,352 new ordinary shares of 1p each in the capital of the Company (the "Ordinary Shares"), at an issue price of 0.17 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company’s closing mid-market price on 17 January 2024.

The new Ordinary Shares are being issued in order to satisfy the fees of certain current and former non-executive directors for the year ending 31 December 2023 (“Fee Shares”), as has been done in previous years.

A total of 12,941,176 Fee Shares will be issued to former non-executive director Mark Wippell and a total of 36,431,176 Fee Shares will be issued to current non-executive directors as set out below:

Director	Current Ordinary Shares held	Fee Shares issued	Resultant holding post Fee Shares	
			Ordinary Shares held	As a percentage of the enlarged share capital on Admission
Nigel Keen	332,267,649	22,313,529	354,581,178	18.70%
Chris Jones	6,479,109	14,117,647	20,596,756	1.09%

Under the contract with Nigel Keen, he or the Company can opt to settle his fees (plus employer’s national insurance) by the issue of new ordinary shares at the share price at the time of issue and the same applies to Chris Jones’ and Ben Carswell’s contracts for up to half of their fees. These share issues are expected to occur on an annual basis when permitted.

Application for admission to trading and total voting rights

Application has been made for 49,372,352 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 24 January 2024 ("Admission").

Following Admission, the Company's issued share capital will comprise 1,896,025,700 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Deltex Medical Group plc
Nigel Keen, Chairman
Andy Mears, Chief Executive
Natalie Wettler, Group Finance Director

01243 774 837
investorinfo@Deltexmedical.com

Nominated Adviser and Broker
Allenby Capital Limited
Jeremy Porter / Vivek Bhardwaj (Corporate Finance)

020 3328 5656
info@allenbycapital.com

Tony Quirke / Stefano Aquilino (Sales & Corporate Broking)

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1.	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	PDMRs:	
		Nigel Keen	Non-Executive Director - Chairman
		Chris Jones	Non-Executive Director
2.	Reason for the Notification		
a)	Position/status	See 1a) above	
b)	Initial notification/Amendment	Initial Notification	
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Deltex Medical Group Plc	
b)	LEI	213800XN34P6LI8J6M39	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 0.1p each in Deltex Medical Group Plc	
	Identification code	ISIN: GB0059337583	
b)	Nature of the transaction	Fee shares	
c)	Price(s) and volume(s)	Name	Price(s)
		Nigel Keen	0.17p
		Chris Jones	0.17p
			Volume(s)
			22,313,529
			14,117,647
d)	Aggregated information:		
	- Aggregated volume	36,431,176	
	- Price	0.17p	
e)	Date of the transaction	18 January 2024	
f)	Place of the transaction	Outside a trading venue	